Chen J T, Hirai Y, Nakayama K, Shimizu Y, Yokosuka K, Teshima H, Hamada T, Fujimoto I, Yamauchi K, Hasumi K
Department of Gynecology, Cancer Institute Hospital, Tokyo.
Nihon Sanka Fujinka Gakkai Zasshi. 1989 Oct;41(10):1565-70.
Six patients with recurrent ovarian cancer who had prior chemotherapy were studied for the clinical efficacy of CDDP-ACR treatment. Five out of the 6 had received CDDP a total doses of 1,320, 780, 750, 475, and 340 mg. CDDP-ACR therapy consisted of continuous infusion of CDDP at a daily dose of 10 mg/m2 over 14 days (total CDDP doses; 140 mg/m2) and of intermittent infusion of ACR (aclarubicin) at a dose of 20 mg/body every other day (total ACR doses: 140 mg). There were one CR and five PR and a response rate up to 100% was noted. Toxicity was manifested in slight nausea or vomiting, but there was no nephrotoxicity. However bone marrow was severe. Thrombocytopenia less than 50,000/mcl in 4 pts (67%) and leukopenia less than 1,000 mcl in 3 pts (50%). The mean filterable platinum exposure measured by area under the concentration-time curve (AUC) was as high as 19.7 +/- 6/0 mg.hr/ml. In conclusion the bone marrow toxicity in this regimen was severe, but the therapeutic efficacy was promising. Further studies on the appropriate infusion time and the minimum effective dose of CDDP are needed.
对6例曾接受过化疗的复发性卵巢癌患者进行了顺铂-阿克拉霉素（CDDP-ACR）治疗的临床疗效研究。6例患者中有5例接受过顺铂治疗，总剂量分别为1320、780、750、475和340毫克。CDDP-ACR治疗包括连续14天每天以10毫克/平方米的剂量输注顺铂（顺铂总剂量；140毫克/平方米），以及每隔一天以20毫克/体的剂量间歇输注阿克拉霉素（阿柔比星）（阿克拉霉素总剂量：140毫克）。有1例完全缓解（CR）和5例部分缓解（PR），观察到缓解率高达100%。毒性表现为轻微恶心或呕吐，但无肾毒性。然而骨髓毒性严重。4例患者（67%）血小板减少至低于50,000/微升，3例患者（50%）白细胞减少至低于1,000/微升。通过浓度-时间曲线下面积（AUC）测量的可滤过铂平均暴露量高达19.7±6.0毫克·小时/毫升。总之，该方案的骨髓毒性严重，但治疗效果有前景。需要进一步研究顺铂的合适输注时间和最低有效剂量。
